We create protein-based immunotherapies targeting the immune synapse to treat cancer, autoimmune/inflammatory disorders, and other diseases.
Alpine Immune Sciences capitalizes on our unique understanding of the immune synapse, using our directed evolution platform to engineer native immune system proteins for therapeutic benefit.
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced two upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting to be held November 9-11, 2018 in Washington, D.C.
At Alpine Immune Sciences, we are applying our platform discovery technology to bring innovative new drugs to people living with cancer and autoimmune/inflammatory diseases
Alpine’s powerful directed evolution platform is based upon proteins native to the immune synapse, engineering potentially novel “Variant immunoglobulin domains” or “vIgDs”. Our vIgDs can engage multiple targets simultaneously, can be significantly more potent then native proteins, and have the potential improve therapeutic outcomes for the treatment of cancer, autoimmune/inflammatory conditions, or infectious diseases.
Because vIgDs are based upon natural participants in the immune synapse, they potentially provide a mechanistic advantage over larger, more artificial constructs.
ALPN-101 is a dual ICOS/CD28 antagonist being developed for the treatment of autoimmune and inflammatory diseases. It is targeted to being clinical studies in Q1-2019, starting with a healthy volunteer study and moving towards acute GvHD and Psoriatic Arthritis.
ALPN-202 is a dual PD-L1/CTLA-4 antagonist with PD-L1 dependent CD28 costimulation being developed for the treatment of cancer. It is targeted to enter the clinic in Q4-2019.
Our Transmembrane Immunomodulatory Protein (TIP) program potentially enhances Engineered Cellular Therapies (ECTs) like CAR-T, TCR, and TIL. TIPs are based upon our core vIgD technology, but are engineered to become part of ECTs to potentially increase specificity, persistence, and/or efficacy.